CoChat

Targeting bile acids and lipotoxicity for NASH treatment

Open access
Chiang, John Y. L. · 2017 · Hepatology Communications
Cited by 32

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Potential conflict of interest: Nothing to report. See Article On Page 1024 Supported by National Institutes of Health Blueprint for Neuroscience Research awards DK44442 and DK58379. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 20%‐30% of the population in Western countries. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD that can develop into cirrhosis and hepatocellular carcinoma (HCC). However, the underlying mechanism of progression of steatosis to NASH and cirrhosis is poorly understood. Multiple factors, including insulin resistance, inflammation, oxidative stress, lipotoxicity, and bile acid toxicity, have been implicated in NASH progression. The bile acid‐activated receptors farnesoid X receptor (FXR) and G‐protein bile acid receptor‐1 are metabolic integrators that function in the regulation of hepatic metabolism and homeostasis. Bile acids are derived from cholesterol in the liver and are secreted into the gastrointestinal system for nutrient absorption. The gut‐to‐liver axis plays a critical role in the regulation of bile acid synthesis and homeostasis. In the intestine, bile acids activate FXR to induce fibroblast growth factor 15 (FGF15) in mice or FGF19 in humans (Fig. 1). FGF15 and FGF19 are secreted into portal circulation to activate the hepatic FGF receptor 4/β‐Klotho complex, which inhibits cholesterol 7α‐hydroxylase (CYP7A1), the key regulatory enzyme in bile acid synthesis. Activation of FXR by bile acids and FXR agonists has been shown to reduce hepatic lipogenesis and improve glucose tolerance and insulin resistance in diet‐induced obese mouse models.Figure 1: Targeting to bile acid and lipid metabolism in NASH treatment. Bile acids are synthesized from cholesterol in hepatocytes. Cyp7a1 is the first and rate‐limiting enzyme in the classic bile acid synthesis pathway to synthesize CA and CDCA. Cyp8b1 is required for synthesis of CA. Cyp27a1 is involved in steroid side‐chain oxidation. The alternative pathway is initiated by Cyp27a1, followed by Cyp7b1. Bile acids are conjugated to amino acids glycine and taurine for secretion into bile. In mice, CDCA is converted to α‐ and β‐muricholic acids. CDCA activates FXR to induce a negative factor, SHP, which inhibits Cyp7a1 and Cyp8b1 gene transcription. Bile acids are stored in the gallbladder and secreted into the gastrointestinal tract for nutrient absorption. In the intestine, conjugated bile acids are deconjugated by bacterial BSH and bacterial 7‐dehydroxylase activities convert CA and CDCA to DCA and LCA, respectively. In the ileum, FXR induces FGF15 (or human FGF19). Bile acids and FGF15/FGF19 are secreted into portal blood for circulation to the liver. In hepatocytes, FGF15 and FGF19 activate the FGF receptor 4/β‐Klotho complex to activate cJun/ERK1/2 of the MAPK pathway to inhibit Cyp7a1 gene transcription. Conjugated bile acid‐activated S1PR2 may also be involved in inhibiting Cyp7a1. In NAFLD and NASH, hepatic bile acid and lipid metabolisms are impaired to accumulate toxic bile acids and lipids along with cholestatic liver injury. Ceramides and diacylglycerols have been linked to insulin resistance in diabetes. FGF19 and M70 inhibit bile acid synthesis and reduce bile acid hydrophobicity. FGF19 and M70 stimulate fatty acid oxidation and inhibit fatty acid synthesis to reduce lipogenesis, ceramides, and diacylglycerol and to increase unoxidized‐cardiolipins in mitochondria; reduced ROS reduces inflammatory cytokines and chemokines (CCl2, Ccr2, IL‐1β, Tnf‐α), fibrosis markers (Col1a1, Timp2), and apoptosis markers (Bax, Bad). In colon, activation of TGR5 stimulates cAMP and secretion of GLP‐1 to improve insulin sensitivity. Abbreviations: BSH, bile salt hydrolase; CA, cholic acid; cAMP, cyclic adenosine monophosphate; CCl2, (C‐C motif) ligand 2; Ccr2, (C‐C motif) receptor 2; CDCA, chenodeoxycholic acid; Col1a1, collagen, type I, alpha 1; Cyp27a1, mitochondria sterol 27‐hydroxylase; Cyp7a1, cholesterol 7α‐hydroxylase; Cyp7b1, oxysterol 7α‐hydroxylase; Cyp8b1, sterol 12α‐hydroxylase; DAG, dystroglycan; DCA, deoxycholic acid; ERK, extracellular signal‐regulated kinase; GLP‐1, glucagon‐like peptide‐1; Icam1, intercellular cell adhesion molecule 1; IL‐1β, interleukin‐1β; LCA, lithocholic acid; MAPK, mitogen‐activated protein kinase; Mmp2, matrix metalloproteinase 2; Nlrp3, nucleotide‐binding domain and leucine‐rich repeat containing protein 3; NTCP, sodium‐taurocholate cotransporting polypeptide; Ostα/β, organic solute transporter alpha/beta; ROS, reactive oxygen species; S1PR2, sphingosine‐1‐phosphate receptor 2; SHP, small heterodimer partner; TCA, trichloroacetic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TGR5, G protein‐coupled bile acid receptor 1; Timp2, tissue inhibitor of metalloproteinase 2; TLCA, taurolithocholic acid; Tnf‐α, tumor necrosis factor alpha; UDCA, ursodeoxycholic acid.Bile acid derivatives that activate FXR

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep4.1127

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Chiang, J. Y. L.
Venue
Hepatology Communications
Published
2017-12
Volume
1
Issue
10
Pages
1002-1004
ISSN
2471-254X (ISSN-L)
OpenAlex
W2774189943
Cited by
32
References
5
FWCI
2.04
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.